title: Effect of porins and plasmid-mediated AmpC beta-lactamases on the efficacy of beta-lactams in rat pneumonia caused by Klebsiella pneumoniae.
abstract: The in vivo activities of imipenem, meropenem, and cefepime were studied in a model of rat pneumonia caused by a plasmid-mediated AmpC beta-lactamase ACT-1-producing Klebsiella pneumoniae strain (K. pneumoniae strain 12) and a derivative porin-deficient mutant (K. pneumoniae strain 12dp). No differences between these activities were seen with K. pneumoniae 12. Only meropenem showed an activity slightly better than that of imipenem with K. pneumoniae 12dp.
authors.affiliation: Servicio de Microbiología, Hospital Son Dureta, IUNICS, Palma de Mallorca, Spain.
authors.forename: Emma
authors.initials: E
authors.lastname: Padilla
authors.forename: Diana
authors.initials: D
authors.lastname: Alonso
authors.forename: Antonio
authors.initials: A
authors.lastname: Doménech-Sánchez
authors.forename: Cristina
authors.initials: C
authors.lastname: Gomez
authors.forename: José Luis
authors.initials: JL
authors.lastname: Pérez
authors.forename: Sebastián
authors.initials: S
authors.lastname: Albertí
authors.forename: Nuria
authors.initials: N
authors.lastname: Borrell
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D001426:Bacterial Proteins / Q000235:genetics / Q000378:metabolism*; D000077723:Cefepime; D002511:Cephalosporins / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D015169:Colony Count, Microbial; D015378:Imipenem / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D066298:In Vitro Techniques; D007710:Klebsiella Infections / Q000188:drug therapy / Q000382:microbiology; D007711:Klebsiella pneumoniae / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics; D008297:Male; D000077731:Meropenem; D008826:Microbial Sensitivity Tests; D010957:Plasmids; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D018272:Porins / Q000172:deficiency* / Q000235:genetics; D051381:Rats; D017208:Rats, Wistar; D013845:Thienamycins / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome; D001618:beta-Lactamases / Q000235:genetics / Q000378:metabolism*; D047090:beta-Lactams / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D002511:Cephalosporins; D018272:Porins; D013845:Thienamycins; D047090:beta-Lactams; D015378:Imipenem; D000077723:Cefepime; C048795:AmpC beta-lactamases; D001618:beta-Lactamases; D000077731:Meropenem